Sugi Predict

Sugi Predict / Compounds / SCHEMBL1063233

SCHEMBL1063233

SCHEMBL1063233

CCOC(=O)c1c(O)c2cccnc2[nH]c1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 1/20 0.62
▸ KDM5B Q9UGL1 1/20 0.62
▸ ALDH1A1 P00352 6/20 0.50
▸ GAA P10253 3/20 0.50
▸ HPGD P15428 2/20 0.50
▸ KDM4E B2RXH2 4/20 0.47
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ LMNA P02545 1/20 0.46
▸ MAPT P10636 2/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ MCL1 Q07820 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ ALOX5 P09917 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1055294 0.86 KDM5A (0.49) KDM5AKDM5BALDH1A1GAAHPGD
SCHEMBL11164924 0.86 KDM5A (0.49) KDM5AKDM5BALDH1A1GAAHPGD
SCHEMBL5761859 0.83 ALDH1A1 (0.60) KDM5AKDM5BALDH1A1GAAHPGD
SCHEMBL11168705 0.82 HTR6 (0.50) KDM5AKDM5BALDH1A1GAAHPGD
SCHEMBL11179300 0.81 KDM5A (0.45) KDM5AKDM5BALDH1A1GAAHPGD
SCHEMBL4518985 0.81 AURKA (0.53) KDM5AALDH1A1GAAKDM4EMEN1
SCHEMBL8802643 0.81 KDM4E (0.59) KDM5AKDM5BALDH1A1GAAHPGD
SCHEMBL249874 0.81 KMT2A (0.49) KDM5AKDM5BALDH1A1GAAHPGD
SCHEMBL2087419 0.80 KDM5A (0.56) KDM5AKDM5BALDH1A1GAAHPGD
SCHEMBL24500307 0.80 KDM5A (0.59) KDM5AKDM5BALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115835909-B Cannabinoid receptor type 2 (CB 2) modulators and uses thereof 泰昂治疗公司 2026-05-15 — — CN disclosed
US-20230143502-A1 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF TEON THERAPEUTICS, INC 2023-05-11 — — US disclosed
WO-2023081730-A1 4-HYDROXY-2-OXO-1,2-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER TEON THERAPEUTICS, INC. (US) 2023-05-11 — — WO disclosed
WO-2023081730-A1 4-HYDROXY-2-OXO-1,2-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER TEON THERAPEUTICS, INC. (US) 2023-05-11 — — WO disclosed
US-20230143502-A1 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF TEON THERAPEUTICS, INC 2023-05-11 — — US disclosed
CN-115835909-A Cannabinoid receptor type 2 (CB 2) modulators and uses thereof 泰昂治疗公司 2023-03-21 — — CN disclosed
EP-4146345-A2 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF Teon Therapeutics, Inc. (US) 2023-03-15 — — EP disclosed
US-11564928-B1 Cannabinoid receptor type 2 (CB2) modulators and uses thereof TEON THERAPEUTICS, INC. (US) 2023-01-31 — — US disclosed
WO-2021226206-A2 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF TEON THERAPEUTICS, INC. (US) 2021-11-11 — — WO disclosed
EP-2247588-B1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-04-13 — — EP disclosed
US-8399449-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-03-19 — — US disclosed
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 — — US disclosed
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 — — US disclosed
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 — — US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 — — US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 — — US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 — — US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143502-A1 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF CNR2, CNR1, GPR18 KDM5A 4067/4885KDM5B 3486/4885ALDH1A1 3600/4885
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 KDM5A 444/4885KDM5B 512/4885ALDH1A1 745/4885
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 KDM5A 483/4885KDM5B 519/4885ALDH1A1 776/4885
US-11564928-B1 Cannabinoid receptor type 2 (CB2) modulators and uses thereof CNR2, CNR1, GPR18 KDM5A 4067/4885KDM5B 3486/4885ALDH1A1 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.